OOIR: Observatory of International Research

Papers

(The TQCC of Nature Reviews Rheumatology is 12. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)

Article	Citations
Low-dose rituximab can go even lower	709
No benefit from adding MTX to ustekinumab	456
Inflammatory arthritis affects men’s fertility	384
Bimekizumab effective across the axSpA spectrum	373
SLC26A2 deficiency, matrix stiffness and mechanotransduction linked in osteoporosis	282
Genome-wide mutagenesis reported in systemic sclerosis	265
The role of the patient in rheumatology	256
Rheumatic diseases on the rise	231
Reply to ‘Potential benefit of anticoagulation in Behçet syndrome’	209
A role for TGFβ and EBV in MIS-C pathogenesis	182
COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations	176
Biological and clinical roles of IL-18 in inflammatory diseases	161
Towards better management of sterile bone inflammation	158
New drug formulation reduces bone loss	145
Use of platelet-rich plasma for knee OA not supported by RCT results	141
To choose or not? The value of discrete-choice experiments in rheumatology	136
Urchin-like nanoparticles for miRNA therapy of OA	131
The value of comparative efficacy studies in informing rheumatology guidelines	131
The 2022 ACR vaccination guideline: a call-to-action	130
Down syndrome: insights into autoimmune mechanisms	125
Inflammation across tissues: can shared cell biology help design smarter trials?	119
Appraising the evolving landscape of protease inhibition in osteoarthritis	118
2021 ACR guideline for JIA reflects changes in practice	117
Imbalance of threat and soothing systems in fibromyalgia: rephrasing an established mechanistic model?	113
FOXP3 splice variant is associated with autoimmune disease	108

MIS-C: myths have been debunked, but mysteries remain	107
Addressing the challenge of global delays in diagnosis and treatment of systemic lupus erythematosus	106
Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician	105
Low-dose glucocorticoids benefit seniors with RA	101
Low back pain is a growing concern	99
Co-trimoxazole reduces mortality in anti-MDA5-DM	99
Guiding ILD management in systemic autoimmune rheumatic diseases	97
Wnt-induced IGF1 drives OA	93
Pain in systemic lupus erythematosus: emerging insights and paradigms	93
Author Correction: Proposals for the rheumatological use of JAK inhibitors	92
Biologics in rheumatoid arthritis: a lifetime treatment or possibility of drug holidays?	92
A direct link between SARS-CoV-2 and bone loss	89
S100A4 inhibition targets fibrosis in SSc	89
Rheumatic diseases and metabolism: where centre and periphery meet	87
Fumarate drives interferon release in systemic sclerosis monocytes	86
Calprotectin tracks tocilizumab-treated RA	83
Distinct mucosal endotypes as initiators and drivers of rheumatoid arthritis	81
Rheumatology in the digital health era: status quo and quo vadis?	81
Sexual dimorphism in the prevalence, manifestation and outcomes of axial spondyloarthritis	78
Publisher Correction: Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician	78
Antibiotics keep rheumatic heart disease at bay	74
Erosive cargo from synovial fibroblasts	73
Targeting the IVD clock to halt degeneration	72
Which DMARD for ICI-associated arthritis?	70
sCD13 role in arthritis mediated via bradykinin receptor	70
Publisher Correction: Recent advances in the diagnosis and management of neuropsychiatric lupus	69
A path towards personalized medicine for autoinflammatory and related diseases	68
PGE2 receptor antagonist has potential to treat osteoarthritis	64
Chimeric receptors broaden the therapeutic landscape for autoimmune disease	64
Macrophage-coated nanocarriers for gouty arthritis	64
CAR T cells induce drug-free SLE remission	64
Cell-free DNA fragmentation signatures link cancer and autoimmunity	64
ERAP1 and the return of the UPR in ankylosing spondylitis	64
Insights into IVDD pathogenesis in 2024	64
Phase III trial of telitacicept in SLE	62
International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative	59
Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach	57
TASL has a key role in SLE	54
RA risk from occupational inhalation	54
PPIs linked to increased risk of knee replacement	53
Blocking CDK7 attenuates inflammatory arthritis	53
Improving the design of RCTs in non-radiographic axial spondyloarthritis	53
Two sides of management recommendations for psoriatic arthritis	50
Repolarizing macrophages using antagomirs	48
New hope for B cell-targeting therapy in pSS	47
New developments in electronic health record analysis	47
A leading role for interferon as a treatment target in Sjögren syndrome	47
A critical view of WHO guidelines on management of low back pain	46
Profiling joint tissues at single-cell resolution: advances and insights	45
Platelets as drivers of immunothrombosis in rheumatic diseases	43

All fibroblasts are equal, but some are more equal than others	42
New refinements aim to optimize articular cartilage tissue engineering	42
Pan American League of Associations for Rheumatology recommendations for the management of axial spondyloarthritis	41
APOE in fat pad and synovium contributes to knee OA	40
Publisher Correction: The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET	39
Clarity for the language of race, ethnicity and genetic ancestry in rheumatology	38
Author Correction: Glycobiology of rheumatic diseases	38
Piezo1 induces new bone formation in AS	36
AhR promotes suppressor cell function in Sjögren syndrome	36
Pathogenic antibodies target stromal antigens in RA	35
The obesity–inflammation axis in psoriatic disease: mechanisms and therapeutic strategies	35
Treg cell-inducing nanoparticles show promise for treating OA	34
Sex- and gender-based personalized medicine in rheumatology	34
CXCL5 effective in mouse model of SLE	34
Imaging for prediction of RA development	33
l-arginine inhibits arthritis and bone loss by reprogramming osteoclast metabolism	33
IL-1 and autoinflammatory disease: biology, pathogenesis and therapeutic targeting	33
Author Correction: International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative	33
Shifting the SLE management paradigm: challenges and implications	32
PDGFR signalling implicated in anti-resorptive effects of sclerostin blockade	30
Location-specific treatment of chronic inflammatory joint disease	29
HLA autoimmunity risk alleles influence T cell receptor sequences	29
Post-transcriptional checkpoints in autoimmunity	28
In vivo CAR-T cell engineering in refractory SLE	28
Mechanisms and clinical implications of intervertebral disc calcification	27
Critical appraisal of serum urate targets in the management of gout	27
Parathyroid hormone receptor agonists in the management of osteoporosis	25
FABP4 exacerbates RA	25
STING-driven necroptosis linked to autoinflammatory disease	24
BiTE therapy for rheumatic diseases	24
PLG nanoparticles target inflammatory monocytes in SSc	24
Interferon disrupts immune and tissue homeostasis in SLE via CXCL13	24
Detachment promotes RA synovial fibroblast survival and invasiveness	23
Adropin inhibits fibrosis in SSc	22
Multi-omics reveals distinct MPA subtypes	22
Guselkumab effective through 2 years in PsA trial	22
COVID-19 linked to rise in anti-MDA5 autoimmunity	21
Notch signalling mediates OA pain in mice	21
Busting the myth of methotrexate chronic hepatotoxicity	20
Complement therapeutics are coming of age in rheumatology	20
State-of-the-art evidence in the treatment of systemic sclerosis	20
Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis	18
Treatment of non-systemic juvenile idiopathic arthritis	18
How the COVID-19 pandemic has affected rheumatology research	18
Citrulline immunity in RA: CD8+ T cells enter the scene	18
The potential contribution of in silico studies to improved treatment of osteoarthritis	18
Single-cell RNA sequencing sheds light on cell-type specific gene expression in immune cells	18
Synovial fluid as a complex molecular pool contributing to knee osteoarthritis	17
Mechanisms of joint destruction in rheumatoid arthritis — immune cell–fibroblast–bone interactions	17
Update on the pathophysiology and treatment of primary Sjögren syndrome	17
The immune health metric as an indicator of health and disease	17
Undiagnosed axSpA is prevalent in IBD	16
Primary care rheumatology: towards sustainable development in health	16
Shedding light onto the immunometabolic effects of glucocorticoids	16
No benefit to intensive urate lowering in gout	16
The PU.1– IL-9 axis in TH9 cells promotes RA	15
Combination therapy for Behçet uveitis	15
Glycosylation switch in synovial fibroblasts promotes ECM degradation	15
UNC93B1 variants promote SLE via TLR activation	15
Bone-modifying drugs slow OA progression	15
Reversal of inflammatory priming prevents arthritic flares	14
Advances in viscosupplementation and tribosupplementation for early-stage osteoarthritis therapy	14
More than a leaky gut: how gut priming shapes arthritis	14
New guide calls for interdisciplinary approach to TMJ arthritis symptoms	14
The role of the immune system in osteoarthritis: mechanisms, challenges and future directions	14
Rheumatoid arthritis prevention in arthralgia: fantasy or reality?	14
Cellular metabolic adaptations in rheumatoid arthritis and their therapeutic implications	14
Lupus ABC spearheading a new era of collaboration to advance lupus drug development	14
Low-frequency and rare genetic variants associated with rheumatoid arthritis risk	14
T cell differentiation in Sjögren syndrome is regulated by TOX	13
Paediatric glucocorticoid toxicity index: new possibilities in assessment	13
Advances in the calculation of minimal important change estimates for patient-reported outcome measures	13
Reply to: Is classifying SSc-ILD drugs as either immunosuppressive or anti-fibrotic misleading?	13
Global epidemiology of spondyloarthritis	12
Evidence-Based Guideline for the management of osteoporosis in men	12
Current challenges in understanding the epidemiology of calcium pyrophosphate crystal deposition	12
The pathogenesis of gout: molecular insights from genetic, epigenomic and transcriptomic studies	12